Lab File Bio Story Index

Select a story to view it

Story
All test subjects regardless of exact test objective or body weight require a priming dose of 50 mL PE012 delivered orally (sweetener or other flavoring may increase ease of application, depending on subject species), followed by an incubation period of 24 hours. Testing any mutagen-class agent without this priming procedure requires dosages that are inactionable at XEDRA-07's current production rates and the difficulty inherent in PE012 transports.
All test subjects regardless of exact test objective or body weight require a priming dose of 50 mL PE012 delivered orally, followed by a one-hour quarantine observation. Should the subject show macrophenotypic changes in observation (and the planned test isn't to evaluate PE012's effects), the subject is to be terminated and processed, with all reports sent to Administration for archival. If the subject remained unchanged the testing can proceed after 24 hours of incubation, as per the previous protocol.
Recent developments in mutagen production have rendered the previous priming protocol unnecessary. As of today testing can begin with the test compound directly, in the previous post-priming dosage. Should this dose produce no discernible effect, the subject's origin and any data pertaining their location in the last year is to be submitted for archival. Tests can resume after a 24 hour incubation period, provided sufficient compound is still on hand.
All mutagen testing (including priming, observation, main test, dissection, and analysis) is to be conducted in a strictly hands-off manner, using remote-controlled disposable equipment. All samples, remains, equipment and excretions are to be disposed of observing Level 7 biohazard protocols. In case of accidental personnel contact with test subjects after the priming sequence, all exposed personnel are to be isolated, processed by security, and relocated to XEDRA-10 in accordance with biohazard transfer guidelines.
In light of the facility-wide quarantine and recent developments, mutagen tests may from now on be conducted with direct personnel-subject contact if disposable equipment is not available. All personnel directly involved in such tests are to keep a detailed self-checkup diary including basic biometric data (height, weight, color of eyes, skin pigmentation), report any observed phenotypical changes, and to submit to biweekly medical evaluations. Remains of test subjects and affected personnel are to be processed on-site and stored in tamper-proof biohazard containers until further notice.
To speed up the rate of mutagen research, XEDRA facilities of Level II and above with experience in mutagen handling will receive the information and equipment necessary for on-site mutagen production within the week. All facilities involved will be placed under quarantine until further notice, barring automated supply shipments. Automated security is to be activated and control handed over to the local Melchior uplink. This restriction is to be lifted at the discretion of Administration, or the next-in-line following the established contingency protocols.

Return to Categories Index